P-099 - DIASTOLIC HEART DYSFUNCTION IS ACCOMPANIED BY CARDIAC STEATOSIS AND ELEVATIONS OF MYOCARDIAL AND CIRCULATING CERAMIDE 18:0 IN DB/DB MICE
aBases Metabólicas de Riesgo Cardiovascular, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona. bServei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona. cServei d'Endocrinologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona. dInstitut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Barcelona. eInstitut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, CIBER de Enfermedades Cardiovasculares, CIBERCV, Barcelona.
Introduction: Specific plasma ceramides are associated with stress-induced cardiomyocyte damage. However, it is currently uncertain whether plasma ceramides are also associated with cardiac steatosis and myocardial dysfunction in a mouse model of diabesity (db/db) mice.
Material and methods: Non-obese, db/+ mice (on a C57BL/6J genetic background) were bred to mice both homozygous (db/db) and heterozygous (db/+) for Leprdb (db/+). Gross parameters, biochemistry, lipidomic analysis, and functional and structural of the myocardium were determined at the end of the study.
Results: Plasma levels of glucose were significantly elevated (∼4-fold, p < 0.05) in db/db mice compared with db/+ mice. The db/db mice displayed a mixed dyslipemia, mainly due to increased non-HDL cholesterol (∼ 1.5-fold, p < 0.05) and triglycerides (∼ 1.4-fold, p < 0.05), and increased levels of free fatty acids (∼ +11%, p < 0.05). This phenotype was accompanied by an exacerbated hepatic (liver triglycerides: .5-fold, p < 0.05) and adiposity (.10-fold p < 0.05). Cardiac steatosis was also elevated in db/db mice (myocardial trilglycerides: .3-fold, p < 0.05) compared with non-diabetic mice, but it was not accompanied by a concomitant altered heart weight. Despite this, the E/A ratio was significantly altered (.1.2-fold, p < 0.05) in db/db mice, suggesting a diastolic dysfunction. Interestingly, this phenotype was accompanied by a relative increase in the ceramide (Cer) Cer18:0 species in both myocardial and plasma of diabesic mice.
Conclusions: Severe diastolic dysfunction was associated with a restrictive pattern and enhanced myocardial steatosis and accompanied by plasma elevations of Cer 18:0 in db/db mice.